ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-0.44 Insider Own0.05% Shs Outstand70.69M Perf Week-11.43%
Market Cap28.28M Forward P/E- EPS next Y-0.79 Insider Trans0.00% Shs Float64.98M Perf Month-42.85%
Income-21.30M PEG- EPS next Q-0.20 Inst Own36.50% Short Float0.52% Perf Quarter-55.21%
Sales- P/S- EPS this Y70.90% Inst Trans-5.53% Short Ratio1.77 Perf Half Y-72.79%
Book/sh1.08 P/B0.37 EPS next Y2.50% ROA-37.50% Target Price6.33 Perf Year-86.93%
Cash/sh1.33 P/C0.30 EPS next 5Y- ROE-63.80% 52W Range0.40 - 3.87 Perf YTD-64.29%
Dividend- P/FCF- EPS past 5Y60.00% ROI- 52W High-89.66% Beta2.41
Dividend %- Quick Ratio18.50 Sales past 5Y- Gross Margin- 52W Low0.00% ATR0.06
Employees18 Current Ratio18.50 Sales Q/Q- Oper. Margin- RSI (14)16.93 Volatility12.48% 11.57%
OptionableYes Debt/Eq0.21 EPS Q/Q25.30% Profit Margin- Rel Volume2.19 Prev Close0.41
ShortableYes LT Debt/Eq0.20 Earnings- Payout- Avg Volume191.52K Price0.40
Recom2.00 SMA20-24.04% SMA50-42.76% SMA200-71.41% Volume419,873 Change-3.26%
Jul-09-21Initiated Jefferies Buy $8
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
May-20-22 07:00AM  
May-18-22 07:00AM  
May-10-22 07:00AM  
Apr-27-22 07:00AM  
Apr-06-22 07:00AM  
Apr-01-22 05:00PM  
Mar-28-22 07:00AM  
Mar-25-22 07:00AM  
Mar-18-22 07:00AM  
Mar-15-22 07:00AM  
Jan-21-22 10:55AM  
Jan-20-22 04:05PM  
Jan-18-22 08:06AM  
Jan-11-22 07:00AM  
Jan-06-22 07:00AM  
Dec-06-21 07:00AM  
Nov-22-21 07:00AM  
Nov-10-21 07:00AM  
Oct-26-21 07:00AM  
Oct-22-21 07:00AM  
Oct-18-21 07:00AM  
Oct-14-21 07:00AM  
Sep-28-21 10:11AM  
Sep-27-21 02:30PM  
Sep-22-21 07:00AM  
Sep-21-21 07:00AM  
Sep-13-21 08:38AM  
Sep-09-21 07:00AM  
Aug-06-21 07:00AM  
Aug-04-21 07:00AM  
Jul-27-21 10:38PM  
Jul-13-21 07:00AM  
Jul-09-21 06:08PM  
Jun-14-21 07:11AM  
Jun-08-21 09:04AM  
Jun-04-21 09:04AM  
May-25-21 07:30AM  
May-11-21 07:30AM  
May-07-21 07:24AM  
May-05-21 05:22AM  
Apr-30-21 09:24AM  
Apr-22-21 07:51AM  
Apr-14-21 09:38AM  
Mar-18-21 07:27AM  
Mar-10-21 12:00PM  
Mar-04-21 02:47PM  
Mar-03-21 12:42AM  
Mar-02-21 08:01AM  
Mar-01-21 04:01PM  
Feb-25-21 06:30AM  
Feb-18-21 07:00AM  
Jan-27-21 07:35AM  
Jan-26-21 07:30AM  
Jan-11-21 05:34AM  
Jan-08-21 09:57AM  
Jan-06-21 11:13AM  
Jan-04-21 09:34AM  
Dec-30-20 11:25AM  
Dec-25-20 12:00PM  
Dec-23-20 10:06AM  
Dec-22-20 10:27AM  
Dec-21-20 10:13AM  
Dec-10-20 09:40AM  
Dec-03-20 10:04AM  
Dec-02-20 06:03PM  
Dec-01-20 10:06AM  
Nov-29-20 08:24PM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
Nov-19-20 07:22AM  
Nov-18-20 11:24AM  
Nov-16-20 06:30AM  
Nov-09-20 07:00AM  
Oct-22-20 07:30AM  
Oct-19-20 10:05AM  
Oct-16-20 05:25AM  
Sep-21-20 06:00AM  
Sep-10-20 03:08AM  
Aug-24-20 03:27AM  
Aug-07-20 03:00AM  
Jul-17-20 06:08AM  
Jul-13-20 12:00PM  
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.